Equities Analysts Offer Predictions for OmniAb Q4 Earnings

OmniAb, Inc. (NASDAQ:OABI - Free Report) - Equities researchers at HC Wainwright issued their Q4 2025 earnings estimates for OmniAb in a research report issued on Wednesday, March 19th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.15) for the quarter. HC Wainwright currently has a "Buy" rating and a $11.00 price objective on the stock. The consensus estimate for OmniAb's current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb's FY2029 earnings at ($0.29) EPS.

Separately, Benchmark reduced their price objective on shares of OmniAb from $8.00 to $6.00 and set a "buy" rating for the company in a research note on Thursday, March 20th.

OmniAb Stock Performance

Shares of OABI traded down $0.10 during trading hours on Friday, hitting $2.44. The company had a trading volume of 698,011 shares, compared to its average volume of 538,565. The stock has a market capitalization of $344.57 million, a price-to-earnings ratio of -3.94 and a beta of -0.14. The firm has a fifty day moving average price of $3.31 and a 200-day moving average price of $3.74. OmniAb has a 52-week low of $2.23 and a 52-week high of $5.54.

OmniAb (NASDAQ:OABI - Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. OmniAb had a negative return on equity of 20.97% and a negative net margin of 308.78%. The business had revenue of $10.80 million during the quarter, compared to analysts' expectations of $10.13 million. During the same quarter in the previous year, the business earned ($0.14) earnings per share.

Remove Ads

Institutional Trading of OmniAb

Large investors have recently modified their holdings of the company. Janus Henderson Group PLC boosted its position in OmniAb by 1.1% in the fourth quarter. Janus Henderson Group PLC now owns 7,960,321 shares of the company's stock worth $28,179,000 after purchasing an additional 88,993 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of OmniAb by 4.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,025,674 shares of the company's stock worth $10,711,000 after purchasing an additional 142,513 shares during the period. Geode Capital Management LLC boosted its holdings in shares of OmniAb by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 2,353,442 shares of the company's stock worth $8,333,000 after buying an additional 28,061 shares during the last quarter. State Street Corp grew its position in OmniAb by 1.7% during the third quarter. State Street Corp now owns 2,031,676 shares of the company's stock valued at $8,594,000 after buying an additional 34,654 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in OmniAb by 582.1% during the fourth quarter. JPMorgan Chase & Co. now owns 1,001,797 shares of the company's stock valued at $3,546,000 after buying an additional 854,929 shares during the last quarter. Institutional investors own 72.08% of the company's stock.

Insider Activity at OmniAb

In related news, Director John L. Higgins acquired 125,750 shares of the stock in a transaction that occurred on Thursday, March 20th. The shares were bought at an average price of $2.35 per share, for a total transaction of $295,512.50. Following the completion of the transaction, the director now directly owns 2,762,887 shares in the company, valued at approximately $6,492,784.45. This trade represents a 4.77 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Charles S. Berkman sold 25,489 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $82,584.36. Following the completion of the sale, the insider now owns 343,190 shares in the company, valued at $1,111,935.60. This represents a 6.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 112,260 shares of company stock valued at $376,601 over the last ninety days. Insiders own 8.60% of the company's stock.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.